Sunvozertinib outperforms chemotherapy in EGFR exon20ins lung cancer https://ymaho.com/sunvozertinib-outperforms-chemotherapy-in-egfr-exon20ins-lung-cancer
NEJM: oral sunvozertinib reduces the risk of progression by 35% in NSCLC with EGFR exon20ins mutation. Full analysis of efficacy, toxicity and drug availability. Learn more.
Gedatolisib: Phase 3 success in PIK3CA-mutated cancer https://ymaho.com/gedatolisib-phase-3-success-in-pik3ca-mutated-cancer
Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.
Personalized CRISPR therapy saved an infant: in vivo breakthrough https://ymaho.com/personalized-crispr-therapy-saved-an-infant-in-vivo-breakthrough
A child with the ultra-rare CPS1 mutation survived thanks to personalized CRISPR therapy in 6 months. Learn about the breakthrough in genetic engineering and N-of-1 platforms.
RNA therapy for hereditary cardiomyopathy: breakthrough in treating PLN R14del https://ymaho.com/rna-therapy-for-hereditary-cardiomyopathy-breakthrough-in-treating-pln-r14del
Scientists reversed cellular defects in PLN R14del mutation using RNA therapy. Learn about a new approach to etiotropic treatment of heart failure. Read details.
Vepdegestrant: the first breast cancer protein degrader https://ymaho.com/vepdegestrant-the-first-breast-cancer-protein-degrader
FDA approved vepdegestrant — the first PROTAC degrader for breast cancer with ESR1 mutation. Learn how it destroys resistance and what will change in therapy. Details here.
Gene therapy for OTOF deafness: hearing restoration https://ymaho.com/gene-therapy-for-otof-deafness-hearing-restoration
FDA approved the first gene therapy for hereditary deafness Otarmeni. Learn how a single injection restores hearing in OTOF mutation and changes the market.
DREAM protein: key regulator of aging and mutations | Nature Aging https://ymaho.com/dream-protein-key-regulator-of-aging-and-mutations-nature-aging
Nature Aging study: the DREAM complex controls aging and mutational burden. How reducing its activity extends lifespan and protects against Alzheimer's disease. Read.
SBS5 and SBS18 Signatures: Oxidative Mutations from Smoking https://ymaho.com/sbs5-and-sbs18-signatures-oxidative-mutations-from-smoking
Whole-exome sequencing revealed SBS5 and SBS18 mutations in smokers' cells. Learn about irreversible changes, lung cancer risk, and new diagnostic tests. Read details.
AI predicts brain cancer without biopsy using PET/CT https://ymaho.com/ai-predicts-brain-cancer-without-biopsy-using-pet-ct
Multimodal AI model based on graph neural networks analyzes PET/CT and predicts glioma mutations with >95% accuracy. Non-invasive diagnosis without biopsy. Learn more.
FDA approved the first gene therapy for hereditary deafness https://ymaho.com/fda-approved-the-first-gene-therapy-for-hereditary-deafness
Regeneron's Otarmeni restores hearing to normal in 42% of patients. The therapy treats OTOF gene mutations with a single injection. Learn how AAV vector technology has for the first time restored the ability to hear a whisper.